Antibe Therapeutics Inc (ATBPF)

[GM26]

TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday. All resolutions proposed to the shareholders were approved, including:

The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu);
The re-appointment of Ernst & Young LLP, Chartered Accountants as Antibe’s auditors;
The adoption of the new Restricted Share Unit (“RSU”) Plan;
The option, at the discretion of the Company’s Board, to consolidate Antibe’s common shares at a ratio within a predetermined range at any time prior to May 29, 2019; and
A standard Advance Notice by-law for future nominations of directors by shareholders.
In addition, the Company has granted a new employee options to purchase a total of 100,000 common shares of the Company pursuant to its stock option plan. Each option has an exercise price of $0.37, being yesterday’s closing price of Antibe’s shares, and an expiry date of June 25, 2028. Twenty-five percent of the granted options vest on the grant date and 1/36th of the remaining options vest in each of the subsequent 36 months. The Company also granted BND Projects Inc. 18,000 options for investor relations services. Each option has an exercise price of $0.38, being the 5-day volume weighted average price of Antibe’s shares, vests quarterly starting on the date of the grant, and will expire June 25, 2021.

http://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/antibe-therapeutics-announces-results-of-annual-general-and-special-meeting